In response to the COVID-19 pandemic, Research and the Diagnostic communities have placed demands on the antibody production market that are unprecedented in scale. This spike in demand combined with the global restriction of capacity has emphasized the importance of relying on antibody development and manufacturing partners that employ scalable and robust antibody production and purification capabilities supported by quality management systems that are appropriate for the prospective antibodies’ fields of use.
In this presentation, the speakers will outline Merck’s contract antibody development, manufacturing, purification, and cell banking capabilities and capacity highlighting investments made to support large-scale recombinant and traditional hybridoma-based antibody production in an industry-leading manufacturing environment.
In this webinar, you will learn about:
- Merck’s contract antibody development, manufacturing, purification, and cell banking capabilities
- Large-scale recombinant and traditional hybridoma-based antibody production
Speakers
Michael Moehlenbrock, Ph.D.
Merck
Business Development Manager - Diagnostic Immunoassays
Michael Moehlenbrock Ph.D. is currently a Business Development Manager and specialist in diagnostic immunoassays for Merck. Before this role, Michael held several roles in product management including head of product management for Merck Research Antibodies portfolio. Michael has his Ph.D., and Bachelor’s degree in Chemistry from St. Louis University where his interdisciplinary research areas of focus included microfluidic analytical chemistry, enzymatic biosensors and biofuels cells, enzymology, and metabolic substrate channeling, and materials chemistry
Sinead McManus
Merck
R&D Manager
Sinead McManus is currently an R&D Manager in the Antibody Discovery group at Merck based in Livingston, Scotland, UK. Sinead earned her B.Sc. in Biotechnology from Dublin City University, Ireland. Sinead joined Merck in 2006 and has held various roles in the company. Sinead has introduced many different single-use manufacturing processes to the Livingston site which are now routinely used by ISCO (Integrated Supply Chain Operations) for antibody production. Sinead oversees the entire process from developing antibodies, scaling and optimizing fermentation conditions, developing purification processes, and transferring the antibodies to production for antibody manufacture.
Jennifer McGrath
Merck
R&D Scientist
Jennifer McGrath is currently an R&D Scientist in the Antibody Discovery group at Merck based in Livingston, Scotland UK. Jennifer earned her B.Sc. in Genetics at The University of Glasgow. Jennifer joined Merck in 2013 as a manufacturing scientist focusing primarily on upstream processing and monoclonal antibody production through tissue culture and fermentation. As an R&D Scientist, she is involved in developing antibodies, scaling, and optimizing new products, and improving current processes. Jennifer provides technical support to the Livingston facility developing new products and processes to support the supply of diagnostic products.
Protein biology
- Clinical testing and diagnostics manufacturing
Durée:1h
Langue:English
Session 1:présenté(e) November 3, 2022
Pour continuer à lire, veuillez vous connecter à votre compte ou en créer un.
Vous n'avez pas de compte ?